Cidofovir treatment of progressive multifocal leukoencephalopathy in a patient receiving highly active antiretroviral therapy

Mayo Clin Proc. 2001 Nov;76(11):1171-5. doi: 10.4065/76.11.1171.

Abstract

Progressive multifocal leukoencephalopathy (PML), a frequently fatal demyelinating disease caused by JC virus, occurs as an opportunistic infection in patients with acquired immunodeficiency syndrome. Curative therapy has been elusive, but recent reports suggest its improvement after institution of highly active antiretroviral therapy (HAART). We describe a case of PML that developed 6 months after the patient, a 55-year-old man, began to receive HAART. The PML progressed despite good virologic and immunologic response to HAART. Substantial symptomatic and radiographic improvement occurred after the addition of cidofovir to the treatment regimen. We reviewed the scientific literature on this rare occurrence of PML after institution of HAART and describe the patient characteristics, potential pathogenesis, and therapeutic options, including the successful use of cidofovir as an adjunctive agent.

Publication types

  • Case Reports

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy*
  • AIDS-Related Opportunistic Infections / physiopathology
  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Antiretroviral Therapy, Highly Active / adverse effects*
  • Antiviral Agents / therapeutic use*
  • Cidofovir
  • Cytosine / analogs & derivatives*
  • Cytosine / therapeutic use*
  • Humans
  • Leukoencephalopathy, Progressive Multifocal / drug therapy*
  • Leukoencephalopathy, Progressive Multifocal / physiopathology
  • Male
  • Middle Aged
  • Organophosphonates*
  • Organophosphorus Compounds / therapeutic use*
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Organophosphonates
  • Organophosphorus Compounds
  • Cytosine
  • Cidofovir